MedTrace Logo

Efficacy of an App-based CBT Featuring Virtual Reality for Anxiety Disorders

NCT05510804 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2022-08-22

No results posted yet for this study

Summary

Primary aim is to evaluate the efficacy of a (minimally) therapist-guided app-based psychotherapy with virtual reality exposure therapy (ALISA) in participants with agoraphobia with or without panic disorder, social anxiety disorder or panic disorder. Participants are diagnosed applying a structured clinical interview by qualified psychologists and then they are randomly allocated to either the intervention group (ALISA) or a control group, receiving supportive psychotherapy while on a waiting list for a structured therapy programme. The investigators hypothesize that participants receiving ALISA compared to controls will present lower levels of anxiety and a higher quality of life at six-month follow-up after start of the intervention, according to Beck Anxiety Inventory (BAI, primary outcome measure) and WHO-QoL, respectively.

Conditions

  • Anxiety
  • Social Phobia
  • Panic Disorder
  • Agoraphobia

Interventions

COMBINATION_PRODUCT

ALISA

assisted self-help smartphone application featuring virtual reality within a structured CBT programme / low-frequency scheduled therapist assistance

Sponsors & Collaborators

  • Zentrum für Integrative Psychiatrie

    collaborator OTHER

  • Bartosz of Zurowski

    lead OTHER

Principal Investigators

  • Bartosz Zurowski · Zentrum für Integrative Psychiatrie, Univ. of Luebeck

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-03
Primary Completion
2022-10-01
Completion
2023-03-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05510804 on ClinicalTrials.gov